METOCLOPRAMIDE Drug Patent Profile
When do Metoclopramide patents expire, and when can generic versions of Metoclopramide launch?
Metoclopramide is a drug marketed by Avet Lifesciences, Baxter Hlthcare Corp, Bedford, Fresenius Kabi Usa, Hospira, Lyphomed, Norbrook, Smith And Nephew, Teva Pharms Usa, Actavis Mid Atlantic, Ani Pharms, Chartwell Molecular, Morton Grove, Paco, Pai Holdings, Pharmobedient Cnsltg, Roxane, Teva, Vistapharm Llc, Novel Labs Inc, Aiping Pharm Inc, Chartwell Rx, Clonmel, Halsey, Impax Labs Inc, Interpharm, Ipca Labs Ltd, Mutual Pharm, Northstar Hlthcare, Par Pharm, Sandoz, Schering, Strides Pharma Intl, Sun Pharm Industries, Superpharm, Usl Pharma, and Watson Labs. and is included in fifty-six NDAs.
The generic ingredient in METOCLOPRAMIDE is metoclopramide hydrochloride. There is one drug master file entry for this compound. Forty suppliers are listed for this compound. Additional details are available on the metoclopramide hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Metoclopramide
A generic version of METOCLOPRAMIDE was approved as metoclopramide hydrochloride by TEVA on July 29th, 1985.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for METOCLOPRAMIDE?
- What are the global sales for METOCLOPRAMIDE?
- What is Average Wholesale Price for METOCLOPRAMIDE?
Summary for METOCLOPRAMIDE
| US Patents: | 0 |
| Applicants: | 37 |
| NDAs: | 56 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 81 |
| Clinical Trials: | 306 |
| Drug Prices: | Drug price information for METOCLOPRAMIDE |
| What excipients (inactive ingredients) are in METOCLOPRAMIDE? | METOCLOPRAMIDE excipients list |
| DailyMed Link: | METOCLOPRAMIDE at DailyMed |
Recent Clinical Trials for METOCLOPRAMIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Montefiore Medical Center | PHASE4 |
| Mercy Bon Secours Saint Vincent Medical Center | PHASE3 |
| Umraniye Education and Research Hospital | NA |
Pharmacology for METOCLOPRAMIDE
| Drug Class | Dopamine-2 Receptor Antagonist |
| Mechanism of Action | Dopamine D2 Antagonists |
US Patents and Regulatory Information for METOCLOPRAMIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interpharm | METOCLOPRAMIDE HYDROCHLORIDE | metoclopramide hydrochloride | TABLET;ORAL | 071213-001 | Sep 24, 1986 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novel Labs Inc | METOCLOPRAMIDE HYDROCHLORIDE | metoclopramide hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202191-002 | Aug 15, 2014 | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sandoz | METOCLOPRAMIDE HYDROCHLORIDE | metoclopramide hydrochloride | TABLET;ORAL | 070850-001 | Feb 3, 1987 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Watson Labs | METOCLOPRAMIDE HYDROCHLORIDE | metoclopramide hydrochloride | TABLET;ORAL | 070363-001 | Mar 2, 1987 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
